Ascendent Capital Partners is a private equity firm focused on acquiring and investing in China-related companies. The Firm looks to leverage its network and experience when working with and helping companies grow. Ascendant Capital Partners has offices in Shanghai and Hong Kong.
Join Mergr to view the latest updates and news from Ascendent Capital Partners.
In the last 3 years, Ascendent Capital Partners has acquired 1 company.
Ascendent Capital Partners’ most common sector for investment is life science (100%). The Firm’s most common investment types include going private (100%). In total, Ascendent Capital Partners has invested in 1 US state. Its largest (disclosed) acquisition occurred in 2017 when it acquired SciClone Pharmaceuticals for $605M.
Join Mergr to view Ascendent Capital Partners’ full profile and discover more middle-market private equity firms just like it.
No obligation. Cancel anytime.